AIP
ZNTL icon

Ameritas Investment Partners’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Ameritas Investment Partners’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,837
Closed -$9.28K – 3362
2025
Q1 		$9.28K Hold
5,837
– – ﹤0.01% 2844
2024
Q4 		$17.7K Hold
5,837
– – ﹤0.01% 2684
2024
Q3 		$21.5K Hold
5,837
– – ﹤0.01% 2622
2024
Q2 		$23.9K Hold
5,837
– – ﹤0.01% 2538
2024
Q1 		$92K Hold
5,837
– – ﹤0.01% 1790
2023
Q4 		$88.4K Hold
5,837
– – ﹤0.01% 1822
2023
Q3 		$117K Buy
5,837
+1,780
+44% +$45.2K ﹤0.01% 1540
2023
Q2 		$114K Buy
4,057
+376
+10% +$9.02K ﹤0.01% 1497
2023
Q1 		$63.3K Hold
3,681
– – ﹤0.01% 1827
2022
Q4 		$84.6K Hold
3,681
– – ﹤0.01% 1716
2022
Q3 		$79K Buy
3,681
+929
+34% +$25.4K ﹤0.01% 1671
2022
Q2 		$77K Hold
2,752
– – ﹤0.01% 1686
2022
Q1 		$127K Hold
2,752
– – ﹤0.01% 1481
2021
Q4 		$231K Hold
2,752
– – 0.01% 1142
2021
Q3 		$183K Buy
2,752
+145
+6% +$8.37K 0.01% 1270
2021
Q2 		$139K Buy
2,607
+199
+8% +$10.7K 0.01% 1521
2021
Q1 		$104K Hold
2,408
– – ﹤0.01% 1648
2020
Q4 		$125K Buy
2,408
+1,495
+164% +$67.4K 0.01% 1439
2020
Q3 		$30K Hold
913
– – ﹤0.01% 2171
2020
Q2 		$44K Buy
+913
New +$35K ﹤0.01% 1915

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Ameritas Investment Partners's ZNTL Position: Q2 2025 in Review

Ameritas Investment Partners sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2025, closing a stake of 5,837 shares — an estimated $9.28K sold.

Ameritas Investment Partners first reported a position in ZNTL in Q2 2020 and held it in 20 quarters. The position peaked at $231K in Q4 2021. 117 funds tracked by Wall St. Rank hold ZNTL as of Q2 2025.

  • Ameritas Investment Partners reported no remaining Zentalis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Ameritas Investment Partners sold 5,837 Zentalis Pharmaceuticals shares in Q2 2025, an estimated $9.28K.
  • Ameritas Investment Partners first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 20 quarters.
  • Ameritas Investment Partners's Zentalis Pharmaceuticals position peaked at $231K in Q4 2021.
  • 117 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2025.

Based on Ameritas Investment Partners's 13F filing for Q2 2025, filed 12 Aug 2025.